Third drugs were introduced, respectively, at 2.17 1.72 years and five.55 2.33 years from the

Third drugs were introduced, respectively, at 2.17 1.72 years and five.55 2.33 years from the starting in the therapy.J. Clin. Med. 2021, 10,five ofTable 1. Demographic and clinical Furazolidone-d4 Purity & Documentation information of individuals at baseline. Proteinuria and creatinine clearance levels are presented as imply regular deviation (SD). Gender Male Female Mutation absent COL4A3 heterozygote COL4A4 heterozygote COL4A5 heterozygote COL4A5 hemizygote COL4A3 homozygote COL4A4 homozygote COL4A3 e COL4A5 dygenic COL4A4 e COL4A5 dygenic Age at the onset of therapy (years) 10.55 5.02 Proteinuria at onset (uPCR mg/mg) 1.46 1.42 Estimated GFR at onset (mL/min/1.73sm) 155.93 49.31 Serum K at onset (mmol/L) four.29 0.37 3 1 two 11 5 1 1 1 1 10 (38.five) 16 (61.5)three.2. Proteinuria In Table two uPCR Share this post on: